Brief: Somalogic Acquires DNA Nanotechnology Leader Palamedrix To Develop The Next-Generation Somascan® Assay
26/07/2022 13:15
July 26 (Reuters) - Somalogic Inc SLGC.O :
* SOMALOGIC ACQUIRES DNA NANOTECHNOLOGY LEADER PALAMEDRIX TO
DEVELOP THE NEXT-GENERATION SOMASCAN® ASSAY
* SOMALOGIC INC - UNDER TERMS OF MERGER AGREEMENT, SOMALOGIC
WILL
PAY AT CLOSING $35 MILLION
* SOMALOGIC INC - TRANSACTION IS EXPECTED TO CLOSE IN Q3 OF
2022
AND IS NOT EXPECTED TO CONTRIBUTE TO SOMALOGIC 2022 REVENUE
* SOMALOGIC -TO OBTAIN INTELLECTUAL PROPERTY COVERING
PALAMEDRIX'S
CORE DNA-BASED TECHNOLOGY PLATFORM FOR INTEGRATION OF MOLECULAR
BIOSENSORS ONTO CHIPS
Source text for Eikon: ID:nGNXJXyxY
Further company coverage: SLGC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Somalogic
See all newsBrief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Madryn Asset Management Demands Somalogic’S Board Address Repeated, Unprecedented Adjournments Of Tainted Special Meeting
Brief: Madryn Asset Management Says It Urges All Somalogic Shareholders To Oppose Transaction With Standard Biotools
Brief: Madryn Asset Management Urges Shareholders To Vote “Against” The Proposed Merger And Allow Somalogic To Pursue Value-Enhancing Alternatives
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders